Tatva Chintan Pharma Chem Ltd (NSE: TATVA, BSE: 543321) is a Vadodara, Gujarat-based company in the Custom Synthesis and Specialty CDMO industry. With a market capitalisation of ₹3,671 Cr, it ranks #949 by market cap among the 6,189 Indian listed companies on FinBizNet, and #5 of 13 in Custom Synthesis and Specialty CDMO. At ₹1,569.30 (as of 26 Oct 2026), the share price is 25.8% below its 52-week high of ₹2,113.60 and 50.3% above its 52-week low of ₹1,044.10. The share price is up 22.0% over one year and down 8.9% over three months.
| Current Price | ₹1,569.30 |
|---|---|
| Market Cap | ₹3,671 Cr |
| NSE Symbol | TATVA |
| BSE Code | 543321 |
| Sector | Materials > Chemicals > Speciality Chemicals |
| Sub-Industry | Specialty Chemicals > Custom Synthesis and Specialty CDMO |
| P/E Ratio | 87.3 |
| Return on Equity | 5.53% |
| Return on Assets | 4.01% |
| 52-Week Range | ₹1,044.10 – ₹2,113.60 |
| 1-Year Price Change | +22.0% |
| 3-Month Price Change | -8.9% |
| Beta (1Y) | 0.32 |
| Dividend Yield | 0.13% |
| Headquarters | Vadodara, Gujarat |
| Website | www.tatvachintan.com |
| Revenue | ₹217 Cr |
|---|---|
| Net Profit | ₹21 Cr |
| Net Margin | 9.9% |
| EPS (Basic) | ₹9.17 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and brominated flame retardants. The company serves automotive, refinery, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care, and flavors and fragrances sectors. Tatva Chintan Pharma Chem Limited was incorporated in 1996 and is headquartered in Vadodara, India.
1. Manufacturing of Chemicals-This segment manufactures and sells specialty chemicals.
1. Specialty Chemicals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Anupam Rasayan India Ltd | ₹12,542 Cr | 73 | 5.76% | ₹655 Cr | -2.2% |
| Neogen Chemicals Limited (Neogen) | ₹6,530 Cr | 199.5 | 3.58% | ₹250 Cr | +45.2% |
| Prasol Chemicals Limited | ₹4,238 Cr | 50 | — | ₹434 Cr | — |
| Laxmi Organic Industries Ltd | ₹4,171 Cr | 52.6 | 4.08% | ₹968 Cr | -27.6% |
| Tatva Chintan Pharma Chem Ltd | ₹3,671 Cr | 87.3 | 5.53% | ₹217 Cr | +22.0% |
| Paushak Ltd. | ₹1,527 Cr | 38.8 | 8.22% | ₹84 Cr | — |
| Sunshield Chemicals Ltd. | ₹828 Cr | 25.3 | 17.02% | — | +12.6% |
| Chemcon Speciality Chemicals Limited | ₹724 Cr | 30.7 | 4.80% | ₹65 Cr | -27.6% |
| Dai-Ichi Karkaria Ltd. | ₹224 Cr | -302.2 | -0.40% | — | — |
Listed by market capitalisation. Ratios are shown for context only.
Tatva Chintan Pharma Chem Ltd is trading at ₹1,569.30, with a market capitalisation of ₹3,671 Cr.
Tatva Chintan Pharma Chem Ltd operates in the Materials > Chemicals > Speciality Chemicals space (Specialty Chemicals > Custom Synthesis and Specialty CDMO).
Tatva Chintan Pharma Chem Ltd has a P/E of 87.3 and a return on equity of 5.53%.
Tatva Chintan Pharma Chem Ltd is listed on the NSE under the symbol TATVA and on the BSE under the scrip code 543321.
Tatva Chintan Pharma Chem Ltd's share price is up 22.0% over one year and down 8.9% over three months. Its 52-week range is ₹1,044.10 to ₹2,113.60.
In Q2 FY27, Tatva Chintan Pharma Chem Ltd reported revenue of ₹217 Cr and net profit of ₹21 Cr, with basic EPS of ₹9.17 (consolidated, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.